 | | Vol. 16.23 – 15 June, 2022 |
| |
|
|
| Scientists reported that mRNA decay kinetics within Parkinson’s disease (PD)-relevant pathways were correspondingly disrupted in PD patient neurons and the brain.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported that a short and early dual SMAD and WNT inhibition course was necessary and sufficient to establish robust and lasting cortical organoid neural stem cell (NSC) identity, efficiently suppressing non-cortical NSC fates.
[Nature Cell Biology] |
|
|
|
| Investigators developed a novel engineering method for creating the chimeric human cerebral organoids to assess the differential roles of apolipoprotein E4 (APOE4) in neurons and astrocytes.
[Signal Transduction and Targeted Therapy] |
|
|
|
| The authors showed that TWIST1 was methylated on lysine-33 at chromatin by SET domain-containing protein 6 (SETD6), a methyltransferase with expression levels correlating with poor survival in glioma patients.
[Nucleic Acids Research] |
|
|
|
| Scientists reported that heat shock transcription factor 1 (HSF1) accumulated in the mitochondria of Huntington’s disease (HD) cell models, a YAC128 mouse model, and human striatal organoids derived from HD induced pluripotent stem cells.
[EMBO Molecular Medicine] |
|
|
|
| Researchers utilized a CSF1R hypomorphic mouse to generate a model of Alzheimer’s disease that genetically lacked microglia.
[Cell Reports] |
|
|
|
| The authors reported the Parkinson’s Disease (PD)-relevant target stearoyl-coA desaturase: inhibiting monounsaturated fatty acids synthesis reversed PD phenotypes.
[npj Parkinson’s Disease] |
|
|
|
| Scientists demonstrated that macrophage migration inhibitory factor (MIF), a multifunctional protein with cytokine/chemokine and chaperone-like activity, inhibited the accumulation and aggregation of misfolded SOD1.
[Scientific Reports] |
|
|
|
|
| Investigators provide an overview of selected emerging therapies that predominantly target processes within the central nervous system (CNS) that are thought to be involved in limiting non-relapsing, progressive disease injury or promoting tissue repair.
[Nature Reviews Neurology] |
|
|
|
| The authors summarize the genetic mutations identified in familial ALS and their clinical features, focusing on SOD1, fused in sarcoma, and transacting response DNA-binding protein.
[Journal of Human Genetics] |
|
|
|
|
| An experimental therapy for ALS, the paralyzing and fatal neurological disorder, has been approved in Canada, adding a new treatment option for a disease for which there are few effective therapies.
[New York Times] |
|
|
|
|
| December 8 – 10, 2022
Los Angeles, California, United States |
|
|
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Flanders Institute for Biotechnology – Antwerp, Belgium |
|
|
|
| | Huntington Medical Research Institutes – Pasadena, California, United States |
|
|
|
| | NTU Lee Kong Chian School of Medicine – Singapore, Singapore |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
